Non-squamous Non-small cell lung cancer
Conditions
Interventions
Pemetrexed plus Bevacizumab as front-line treatment
Sponsors
Department of Respiratory Medicine Kyorin Univercity Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) histologically or cytologically confirmed 2)newly diagnosed stage IIIB,IV 3)recurrent NSCLC for which they had not received chemotherapy 4)measurable or nonmeasurable disease as defined by Response Evaluation Criteria in Solid Tumors 5)age 20-69 Performance status:2 age 70-74 Performance status:1-2 age 75≤ Performance status:0-2 Patients ineligible for platinum-based chemotherapy 6)adequate hematologic, hepatic, and renal functions 7)Patients expected to survive longer than at least three months 8)patients with a history of brain metastases after treatments more than a week ago 9)Patients who provide written informed consent
Exclusion criteria
Exclusion criteria: 1)active double cancer 2)clinically significant infectious disease 3)history of gross hemoptysis (2.5ml) 4)regular use of aspirin 5)history of diverticulitis or clinically significant diverticular disease 6)clinically significant cardiovascular disease and DVT 7)medically uncontrolled hypertension and diabetes 8)active or symptomatic interstitial lung disease 9)Patients with the plan of operation or thoracic irradiation 10)Patients with wound that has not quite healed 11)pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free surviaval | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate, Overall survival, QOL,Time to response,Safety,evaluation of thymidylate synthase protein expression | — |
Countries
Japan
Contacts
Public ContactTakuma Yokoyama
Kyorin Univercity Hospital Department of Respiratory Medicine
Outcome results
None listed